"Ny medicin" mot IBS

Min läkare i stockholm har länge talat om den här medicinen, linaclotide, som släppts i USA under namnet Linzess (tjusigt värre, huu.. ). Medicinen är inte tillgänglig i Europa ännu, men lär väl lanseras som ännu en mirakelmedicin mot IBS med förstoppning - av kronisk variant så att säga. Det har varit flera föregångare, men ingen av dem har väl riktigt slagit och blivit den där fantastiska boten som läkarna och läkemedelsbolagen drömmer om. Patienterna inte minst. Skillnaden är väl att patienterna inte har några pengar att tjäna, "bara" hälsan. Den borde ju gå först oavsett kan man tycka. 

Undrar vad den här medicinen kommer kosta.. med tanke på att resolor gick loss på tusenlappar för en liten ask med en månadsförbrukning...  tja, det återstår att se!

News & Events





Home
News & Events
Newsroom
Press Announcements
-

FDA NEWS RELEASE

For Immediate Release: Aug. 30, 2012
Media Inquiries: Stephanie Yao, 301-796-0394, stephanie.yao@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA

FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation

The U.S. Food and Drug Administration today approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults.

According to the National Institutes of Health, an estimated 63 million people are affected by chronic constipation. Chronic idiopathic constipation is a diagnosis given to those who experience persistent constipation and do not respond to standard treatment. Additionally, an estimated 15.3 million people are affected by IBS. IBS-C is a subtype characterized mainly by abdominal pain and by hard or lumpy stools at least 25 percent of the time and loose or watery stools less than 25 percent of the time.

Linzess is a capsule taken once daily on an empty stomach, at least 30 minutes before the first meal of the day. Linzess helps relieve constipation by helping bowel movements occur more often. In IBS-C, it may also help ease abdominal pain.

“No one medication works for all patients suffering from these gastrointestinal disorders,” said Victoria Kusiak, M.D., deputy director of the Office of Drug Evaluation III in FDA’s Center for Drug Evaluation and Research. “With the availability of new therapies, patients and their doctors can select the most appropriate treatment for their condition.”

The safety and effectiveness of Linzess for the management of IBS-C were established in two, double-blind studies. A total of 1,604 patients were randomly assigned to take 290 micrograms of Linzess or a placebo for at least 12 weeks. Results showed Linzess was more effective in reducing the amount of abdominal pain and increasing the number of complete spontaneous bowel movements compared with placebo.

The safety and effectiveness of Linzess for the management of chronic idiopathic constipation also were established in two, double-blind studies. A total of 1,272 patients were randomly assigned to take Linzess at doses of 145 mcg or 290 mcg or a placebo for 12 weeks. Results from these studies showed patients taking Linzess experienced more complete spontaneous bowel movements than those taking the placebo. The 290 mcg dose is not approved for chronic constipation because studies indicated it was no more effective than the 145 mcg dose.

Linzess is approved with a Boxed Warning to alert patients and health care professionals that the drug should not be used in patients 17 years of age and younger. The most common side effect reported in during the clinical studies was diarrhea.

Linzess is co-marketed by Ironwood Pharmaceuticals Inc., based in Cambridge, Mass., and Forest Pharmaceuticals Inc., based in St. Louis, Mo.

For more information:

FDA Approved Drugs: Questions and Answers

FDA: Drug Innovation

NIH: Constipation

NIH: Irritable Bowel Syndrome



This press release was updated on Aug. 30, 2012 at 12:30 p.m. to correct the age of patients in which this drug should not be used and the companies marketing the product.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

#

Read our Blog: FDA Voice

Visit the FDA on Facebook, Flickr, YouTube and Twitter



Källa: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm317505.htm